Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | NPY2R | P49146 | 13/20 | 0.50 |
| ▸ | MTTP | P55157 | 5/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5127998 | 0.86 | RAB9A (0.48) | NPC1RAB9ASMN1; SMN2NPY2RMTTP | |
| SCHEMBL5128549 | 0.82 | NPY2R (0.62) | NPY2R | |
| SCHEMBL5084475 | 0.77 | NPY2R (0.78) | NPY2RMTTP | |
| SCHEMBL5133101 | 0.70 | CRACR2A (0.56) | NPC1RAB9ASMN1; SMN2NPY2RMTTP | |
| SCHEMBL5132870 | 0.70 | RAB9A (0.52) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL5131350 | 0.69 | KDM4E (0.51) | NPC1RAB9ASMN1; SMN2NPY2RMTTP | |
| SCHEMBL5131438 | 0.69 | RAB9A (0.51) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL5131808 | 0.68 | MAPT (0.70) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL5131781 | 0.68 | NPY2R (0.62) | NPY2R | |
| SCHEMBL27348350 | 0.68 | LMNA (0.66) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183239-B2 | Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-22 | — | — | US | disclosed |
| US-20070100141-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100141-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | NPY2R, NPY5R, NPY4R | NPC1 3192/4885RAB9A 4269/4885SMN1; SMN2 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.